Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Jan;38(1):38–42. doi: 10.1007/BF01517168

Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases

Barbara P Barna 1,✉, Mary Jane Thomassen 3,4, Mary Maier 3,4, Sharon V Medendorp 2, Raymond R Tubbs 1, Theresa Chiang 1, Ping Zhou 1, Belinda Yen-Lieberman 1, Sugatha Singh-Burgess 1, Sharad D Deodhar 1
PMCID: PMC11038352  PMID: 8299117

Abstract

A synthetic peptide (RS-83277) derived from the structure of human C-reactive protein (CRP) was previously shown to have antitumor activity in three different murine tumor models when administered in multilamellar vesicles (MLV). The therapeutic effects were comparable to those seen with MLV-encapsulated native CRP. The present study evaluated the therapeutic and immunomodulatory effects of administering CRP peptide RS-83277 MLV simultaneously with low-dose recombinant interleukin-2 (IL-2) to C57B1/6 mice bearing established pulmonary metastases of fibrosarcoma T241. Results demonstrated that the capacity of RS-83277 MLV to inhibit tumor metastases and prolong survival was significantly augmented by combination with 10 000 U/day IL-2 i.p. Treated animals showed no evidence of toxicity. By immunohistochemistry, increased Thy 1.2+ cells were detectable in lungs of RS-83277 MLV/IL-2-treated animals compared to those receiving RS-83277 MLV alone. Circulating tumor necrosis factor α (TNF) and interferon (IFN) were not detectable in animals receiving RS-83277 MLV alone, but TNF was significantly elevated in animals receiving IL-2. In the presence of combination therapy, however, circulating TNF was not detectable. Results suggest that the combination of synthetic CRP peptide RS-83277 MLV and low-dose IL-2 offers a therapeutic advantage over either agent alone.

Key words: Immunotherapy, C-reactive protein, Liposomes, Interleukin-2, Synthetic peptide

Footnotes

This work was supported in part by grant CA49950 from the National Cancer Institute (B.P.B.), and grant 43618 from the National American Cancer Society (S.D.D.)

References

  • 1.Asao T, Shibata HR, Batist G, Brodt P. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluoroouracil, and leucovorin. Cancer Res. 1992;52:6254. [PubMed] [Google Scholar]
  • 2.Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol. 1989;23:45. doi: 10.1016/0165-5728(89)90072-6. [DOI] [PubMed] [Google Scholar]
  • 3.Barna BP, Eppstein DA, Thomassen MJ, Nestor JJ, Jr, Ho T, Medendorp SV, Deodhar SD. Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models. Cancer Immunol Immunother. 1993;36:171. doi: 10.1007/BF01741088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, Andrejcio K, Cushman MK. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulatin liposomes in patients with advanced cancer. J Biol Response Mod. 1990;9:492. [PubMed] [Google Scholar]
  • 5.Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 1982;42:5084. [PubMed] [Google Scholar]
  • 6.Dinney CPN, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ. Immunotherapy of murine renal carcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or γ-interferon. Cancer Res. 1992;52:1155. [PubMed] [Google Scholar]
  • 7.Fidler IJ. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science. 1980;208:1469. doi: 10.1126/science.7384789. [DOI] [PubMed] [Google Scholar]
  • 8.Fidler IJ, Schroit AJ. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. J Immunol. 1984;133:515. [PubMed] [Google Scholar]
  • 9.Fidler IJ, Fan D, Ichinose Y. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyl tripeptide phosphatidylethanolamine and interferon. Invas Metastasis. 1989;9:75. [PubMed] [Google Scholar]
  • 10.Gautam SC, Fyfe D, Deodhar SD. Augmentation of immune response to syngeneic fibrosarcoma T241 with in vivo protection. Cancer Immunol Immunother. 1979;6:81. [Google Scholar]
  • 11.Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with metastatic cancer treated with recombinant Interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988;48:5864. [PubMed] [Google Scholar]
  • 12.Hanninen EL, Korfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J. Biological monitoring of low dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res. 1991;50:6312. [PubMed] [Google Scholar]
  • 13.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457. [Google Scholar]
  • 14.Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991;9:259. doi: 10.1200/JCO.1991.9.2.259. [DOI] [PubMed] [Google Scholar]
  • 15.Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, LeSher D, Blun RH, Vilcek J. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a Phase II study in patients with metastatic melanoma. J Natl Cancer Inst. 1992;84:694. doi: 10.1093/jnci/84.9.694. [DOI] [PubMed] [Google Scholar]
  • 16.Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Seipp CA, Rosenberg SA. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58:2764. doi: 10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  • 17.Lotze MT, Chang AE, Seipp CA, Simpson CG, Vetto JT, Rosenberg SA. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. J Am Med Assoc. 1986;256:3117. [PubMed] [Google Scholar]
  • 18.Maas RA, Dullens HFJ, Otter WD. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother. 1993;36:141. doi: 10.1007/BF01741084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Malik ST, Martin D, Hart I, Balkwill F. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphatidylethanolamine (MTPPE) and recombinant GM-CSF. Br J Cancer. 1991;63:399. doi: 10.1038/bjc.1991.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Monastra G, Bruni A. Decreased serum level of tumor necrosis factor in animals treated with lipopolysaccharide and liposomes containing phosphatidylserine. Lymphokine Cytokine Res. 1992;11:39. [PubMed] [Google Scholar]
  • 21.Mule JJ, Yang J, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol. 1986;136:3899. [PubMed] [Google Scholar]
  • 22.Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff IH. Phase 1 trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989;7:1915. doi: 10.1200/JCO.1989.7.12.1915. [DOI] [PubMed] [Google Scholar]
  • 23.Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Statist Soc Ser A. 1972;135:185. [Google Scholar]
  • 24.Phillips NC, Tsao MS. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res. 1989;49:936. [PubMed] [Google Scholar]
  • 25.Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced inEscherichia coli . Science. 1984;223:1412. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  • 26.Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985;161:1169. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol. 1986;137:1735. [PubMed] [Google Scholar]
  • 28.Rubin JJ, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res. 1989;49:7086. [PubMed] [Google Scholar]
  • 29.Saiki I, Fidler IJ. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol. 1985;135:684. [PubMed] [Google Scholar]
  • 30.Sheibani K, Tubbs RR. Enzyme immunohistochemistry: technical aspects. Semin Diagn Pathol. 1984;1:235. [PubMed] [Google Scholar]
  • 31.Storm G, Wilms HP, Crommelin DJA. Liposomes and biotherapeutics. Biotherapy. 1991;3:25. doi: 10.1007/BF02175097. [DOI] [PubMed] [Google Scholar]
  • 32.Thomassen MJ, Meeker DP, Deodhar SD, Wiedemann HP, Barna BP. Activation of human monocytes and alveolar macrophages by a synthetic peptide of C-reactive protein. J Immunother. 1993;13:1. doi: 10.1097/00002371-199301000-00001. [DOI] [PubMed] [Google Scholar]
  • 33.Thombre PS, Deodhar SD. Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine. Cancer Immunol Immunother. 1984;16:145. doi: 10.1007/BF00205420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, Huber C, Herold M, Alvord WG, Snow S, Clark JW. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1990;50:2979. [PubMed] [Google Scholar]
  • 35.Vosika GJ, Cornelius DA, Gilbert CW, Sadlik JR, Bennek JA, Doyle A, Hertsgaard D. Phase I trial of ImmTher, a new liposome incorporated lipophilic disaccharide tripeptide. J Immunother. 1991;10:256. doi: 10.1097/00002371-199108000-00004. [DOI] [PubMed] [Google Scholar]
  • 36.Wang A, Lu SD, Mark DF. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science. 1984;224:1431. doi: 10.1126/science.6427925. [DOI] [PubMed] [Google Scholar]
  • 37.Wilcoxon F. Individual comparisons by ranking methods. Biometric Bull. 1945;1:80. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES